Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Jones fractures in patients with metastatic breast cancer (MBC)
    Meeting Abstract

    Van Poznak, C.; Boland, P.; Morris, C.; Dickler, M.; Hudis, C.; Healey, J.
    Bone (2006)

    Fulltext@MSK | Save
  • Osteoprotegerin (OPG) expression in breast tumours and bone metastases
    Meeting Abstract

    Van Poznak, C.; Ottewell, P.; Cross, S.; Hudis, C.; Coleman, R. E.; Holen, I.
    Bone (2006)

    Fulltext@MSK | Save
  • In vivo activity of a novel regimen of capecitabine (C) in a breast cancer xenograft model
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Higgins, B.; Kolinsky, K.; Packman, K.; Dugan, U.; Hudis, C. A.; Norton, L.
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Optimizing chemotherapy administration: A phase I study of biweekly capecitabine dose and schedule based on Norton-Simon mathematical modeling
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Panageas, K.; Hodgman, E.; Norton, L.; Hudis, C. A.
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Traina, T. A.; Rugo, H.; Caravelli, J.; Yeh, B.; Panageas, K.; Bruckner, J.; Norton, L.; Park, J.; Hudis, C.; Dickler, M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC)
    Meeting Abstract

    Sugarman, S. M.; Wasserheit, C.; Hodgman, E.; Coglianese, M. E.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Ductal carcinoma in situ and BRCA mutations: Association and risk factors
    Meeting Abstract

    Smith, K. L.; Adank, M.; Kauff, N.; Lafaro, K.; Boyd, J.; Lee, J.; Hudis, C.; Offit, K.; Robson, M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Combined inhibition of PI3K/AKT and MAPK signaling is required to inhibit translational initiation and to induce apoptosis in human tumors
    Meeting Abstract

    She, Q. B.; Ye, Q.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Inhibition of Hsp90 function downregulates EGFR and sensitizes EGFR-mutant xenografts to paclitaxel
    Meeting Abstract

    Sawai, A.; Greulich, H.; Ye, Q.; Sellers, W.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B)
    Meeting Abstract

    Rugo, H. S.; Dickler, M. N.; Traina, T. A.; Scott, J. H.; Moore, D. H.; Bruckner, J.; Hudis, C.; Park, J. W.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save